

There were 42 participants from fifteen countries.

### Specimens

The round included two human based specimens, which were distributed to participants by mail without any temperature control. The laboratories were requested to analyse the specimens as soon as possible (within a week) and store them in a refrigerator.

**Specimen S001: LQ757218011**      IgA - IgG - IgM -  
**Specimen S002: LQ757218012**      IgA - IgG - IgM -

### Results

In LabScala reports the results are divided into groups according to the method stated by the laboratory.

The qualitative results are presented in laboratory method-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button. Change in the report layout: Please note that by default the distribution pies are closed in the scoring reports. You are able to open the distribution pies by clicking the screen button at the right end of the RESULT DISTRIBUTION row. In the scoring section you can see summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodics counts in the tables. The cumulative scoring data is calculated according to the order of the results. Therefore we recommend you to locate the results of your primary method to the top of the result form.

If you have no results you will get a note that you have not responded on time.

The participants of this EQA scheme are able to report three (3) results for each specimen in LabScala, when the material is sufficient for additional analysis. This opportunity is intended for different test kits or instruments of one testing unit.

### Comments

In the first round of the year, there were two *B. pertussis* antibody negative samples.

Sample S001 was normal human specimen. The clear majority of participants reported negative IgM, IgA and IgG antibodies. IgG antibodies against pertussis toxin were on a low level. As clinical interpretation, "negative, no sign of infection" was the accepted one.

In sample S002, pertussis antibodies were negative in the analyses of the expert laboratory, and all participating laboratories also reported negative antibody results. Negative, no sign of infection" was the expected clinical interpretation.

2018-03-02

### FINAL REPORT

Items sent            2018-01-29  
Round closed        2018-02-23  
Results released    2018-02-27  
Report released     2018-03-02

Product no. 5950  
LQ757218011-012/UK

### The report contains

-Laboratory specific result and scoring tables

### Request for corrections

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing.

Requests must be notified by writing within three weeks from the date of this letter.

### Expert

Dr. Jukka Hytönen, MD, PhD  
University of Turku,  
Finland

### Authorized by

EQA Coordinator  
Satu Eklund  
T. +358 45 773 107 87  
satu.eklund@labquality.fi

### Labquality

Kumpulantie 15  
FI-00520 HELSINKI

### Telephone

+358 9 8566 8200

### Fax

+358 9 8566 8280  
+358 9 8566 8281

info@labquality.fi  
www.labquality.fi

© Labquality



Next page→

## Scores

The round is scored based on test results and clinical interpretations. The specimen will be scored if 60 % of the test results/clinical interpretations in question are correct/expected. Following general rules are followed:

- |  |             |
|--|-------------|
| - Correct negative or positive test result | 2/2 points. |
| - Partly correct test result               | 1/2 points. |
| - False negative or positive test result   | 0/2 points. |
| - Correct clinical interpretation          | 4/4 points. |
| - False clinical interpretation            | 0/4 points. |

Laboratory's scores have been converted to percentage (own success rate, % from maximum scores) with a target at 100%. Own success rate is compared with the success rate of all results.

The reports of this round are available on **Labquality homepage** ([www.labquality.fi](http://www.labquality.fi)). Please **Login to LabScala** and fill in your laboratory's **client code/personal user name** and **password**. Then please choose **My documents** → **View Reports**.

## End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.